Undertreatment of heart failure has high cost to patients

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7288.731/a (Published 24 March 2001) Cite this as: BMJ 2001;322:731
  1. Colin Berry (colin.berry@clinmed.gla.ac.uk), Medical Research Council clinical training fellow,
  2. John McMurray, professor of medical cardiology
  1. Department of Medicine and Therapeutics, Western Infirmary, University of Glasgow, Glasgow G11 6NT

    EDITOR—Chronic heart failure remains a serious public health problem. The diagnosis constitutes a high risk of morbidity and mortality, with a prognosis that is at least as bad as many forms of cancer. Despite this, a high proportion of people with symptoms and signs of chronic heart failure are undiagnosed, and of those who are, many are undertreated.1 The evidence in support of treatment with angiotensin converting enzyme inhibitors, β blockers, and, most recently, spironolactone, is compelling.2 It follows, therefore, …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription